Thor Medical ASA
Company Profile
Business description
Thor Medical ASA is a Norway-based biopharmaceutical company. The company is a producer and supplier of alpha-particle emitters for cancer therapy. The production process is based on separation of natural occurring radioactive decay products from thorium. The Company is utilizing alpha-emitters in radiotherapy and cancer treatments using Pb-212, which can be produced from naturally occurring isotope Thorium-232 and Lead-212. It uses a proprietary production process that does not involve irradiation or nuclear reactors to produce alpha-emitting materials. These materials are used by radiopharmaceutical companies in the development of cancer therapies.
Contact
Drammensveien 167
Oslo0277
NORT: +47 97414000
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
18
Stocks News & Analysis
stocks
Cheap ASX share may have more room to run
stocks
ASX listed media giant drives strong earnings growth
stocks
ASX real estate platform outperforms yet questions remain
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,424.10 | 13.30 | -0.14% |
| CAC 40 | 8,704.15 | 10.78 | -0.12% |
| DAX 40 | 26,408.48 | 89.03 | 0.34% |
| Dow JONES (US) | 54,036.93 | 151.83 | 0.28% |
| FTSE 100 | 10,874.20 | 26.89 | -0.25% |
| HKSE | 25,937.49 | 269.46 | 1.05% |
| NASDAQ | 26,690.62 | 342.26 | 1.30% |
| Nikkei 225 | 66,970.22 | 1,363.51 | 2.08% |
| NZX 50 Index | 13,888.24 | 64.11 | 0.46% |
| S&P 500 | 7,757.64 | 47.68 | 0.62% |
| S&P/ASX 200 | 9,232.60 | 17.00 | -0.18% |
| SSE Composite Index | 3,966.59 | 26.56 | 0.67% |